Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis

Gadhave, Dnyandev G.; Sugandhi, Vrashabh V.; Kokare, Chandrakant R.

doi:10.1016/j.brainres.2023.148674

Cited by 4 publications

(1 citation statement)

References 208 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, though, there have been more than 200 protein therapies that have overcome such hurdles and have been approved by the FDA for wide-ranging therapeutic applications, with many more on the path toward such an approval and implementation [6]. These therapies depend on the ability of a drug delivery system to deliver proteins efficiently and precisely to the targeted site within the body [7,8] by navigating the complex biological pathways of the human body and selectively targeting diseased tissues while sparing healthy ones [9][10][11][12]. This task demands precision engineering and an Micromachines 2024, 15, 533 2 of 21 intimate knowledge of physiological interactions, making it a focal point in current research and developments in the field.…”

Section: Introductionmentioning

confidence: 99%

Biomaterials for Protein Delivery: Opportunities and Challenges to Clinical Translation

Gorantla,

Hall,

Troidle

et al. 2024

Micromachines

View full text Add to dashboard Cite

The development of biomaterials for protein delivery is an emerging field that spans materials science, bioengineering, and medicine. In this review, we highlight the immense potential of protein-delivering biomaterials as therapeutic options and discuss the multifaceted challenges inherent to the field. We address current advancements and approaches in protein delivery that leverage stimuli-responsive materials, harness advanced fabrication techniques like 3D printing, and integrate nanotechnologies for greater targeting and improved stability, efficacy, and tolerability profiles. We also discuss the demand for highly complex delivery systems to maintain structural integrity and functionality of the protein payload. Finally, we discuss barriers to clinical translation, such as biocompatibility, immunogenicity, achieving reliable controlled release, efficient and targeted delivery, stability issues, scalability of production, and navigating the regulatory landscape for such materials. Overall, this review summarizes insights from a survey of the current literature and sheds light on the interplay between innovation and the practical implementation of biomaterials for protein delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Biomaterials for Protein Delivery: Opportunities and Challenges to Clinical Translation

Gorantla,

Hall,

Troidle

et al. 2024

Micromachines

View full text Add to dashboard Cite

show abstract

Optimization of Interleukin‐10 incorporation for dendritic cells embedded in Poly(ethylene glycol) hydrogels

Bulondo,

Babensee

2024

J Biomedical Materials Res

View full text Add to dashboard Cite

Translational research in biomaterials and immunoengineering is leading to the development of novel advanced therapeutics to treat diseases such as cancer, autoimmunity, and viral infections. Dendritic cells (DCs) are at the center of these therapeutics given that they bridge innate and adaptive immunity. The biomaterial system developed herein uses a hydrogel carrier to deliver immunomodulatory DCs for amelioration of autoimmunity. This biomaterial vehicle is comprised of a poly (ethylene glycol)‐4 arm maleimide (PEG‐4MAL) hydrogels, conjugated with the immunosuppressive cytokine, interleukin‐10, IL‐10, and cross‐linked with a collagenase‐degradable peptide sequence for the injectable delivery of immunosuppressive DCs to an anatomical disease‐relevant site of the cervical lymph nodes, for intended application to treat multiple sclerosis. The amount of IL‐10 incorporated in the hydrogel was optimized to be 500 ng in vitro, based on immunological endpoints. At this concentration, DCs exhibited the best viability, most immunosuppressive phenotype, and protection against proinflammatory insult as compared with hydrogel‐incorporated DCs with lower IL‐10 loading amounts. Additionally, the effect of the degradability of the PEG‐4MAL hydrogel on the release rate of incorporated IL‐10 was assessed by varying the ratio of degradable peptides: VPM (degradable) and DTT (nondegradable) and measuring the IL‐10 release rates. This IL‐10‐conjugated hydrogel delivery system for immunosuppressive DCs is set to be assessed for in vivo functionality as the immunosuppressive cytokine provides a tolerogenic environment that keeps DCs in their immature phenotype, which consequently enhances cell viability and optimizes the system's immunomodulatory functionality.

show abstract

Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance

Gadhave,

Sugandhi,

Jha

et al. 2024

Ageing Research Reviews

View full text Add to dashboard Cite

Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: Multiple sclerosis

Cited by 4 publications

References 208 publications

Biomaterials for Protein Delivery: Opportunities and Challenges to Clinical Translation

Biomaterials for Protein Delivery: Opportunities and Challenges to Clinical Translation

Optimization of Interleukin‐10 incorporation for dendritic cells embedded in Poly(ethylene glycol) hydrogels

Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance

Contact Info

Product

Resources

About